Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ribozyme therapy for HIV infection.

J J Rossi1

  • 1Department of Molecular Biology, Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, 91010, USA. jrossi@coh.org

Advanced Drug Delivery Reviews
|October 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A critical assessment of the potential of short interfering RNA therapeutics.

Drug discovery today. Technologies·2014
Same author

Current progress in the development of RNAi-based therapeutics for HIV-1.

Gene therapy·2011
Same author

Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo.

Gene therapy·2009
Same author

Stem cells, ribozymes and HIV.

Gene therapy·2009
Same author

Innate immunity confounds the clinical efficacy of small interfering RNAs (siRNAs).

Gene therapy·2009
Same author

Cholesterol paves the way for topically applied viricides.

Cell host & microbe·2009
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Ribozymes show promise in inhibiting human immunodeficiency virus type 1 (HIV-1) infection. This review details a decade of progress in ribozyme development and clinical trials for HIV-1 gene therapy.

Area of Science:

  • Molecular Biology
  • Virology
  • Gene Therapy

Background:

  • Despite advances in antiretroviral therapy, human immunodeficiency virus type 1 (HIV-1) remains a global health challenge.
  • The emergence of drug-resistant HIV-1 strains necessitates the development of novel therapeutic strategies.
  • Ribozymes have emerged as a potential tool for inhibiting HIV-1 replication.

Purpose of the Study:

  • To review the progress of ribozymes in combating HIV-1 infection over the past decade.
  • To summarize the current status of ribozyme development for HIV-1 inhibition.
  • To highlight the potential of ribozymes as a therapeutic approach for HIV-1.

Main Methods:

  • Review of scientific literature on ribozyme development for HIV-1.
  • Analysis of preclinical and clinical trial data for ribozyme-based HIV-1 therapies.

Related Experiment Videos

  • Summary of advancements in gene therapy approaches utilizing ribozymes.

    • Main Results:

    • Ribozymes have demonstrated efficacy in inhibiting HIV-1 spread in cell culture.
    • Ribozyme-based gene therapy strategies have advanced to human clinical trials.
    • Significant progress has been made in optimizing ribozyme design and delivery for anti-HIV-1 applications.

    Conclusions:

    • Ribozymes represent a promising addition to the therapeutic arsenal against HIV-1.
    • Continued research and development are crucial for realizing the full potential of ribozymes in HIV-1 treatment.
    • Ribozyme-based therapies offer a potential long-term strategy for managing HIV-1 infection.